Open AccessS958 Pharmacogene CYP1A2*1F Polymorphism Lowers Anti-TNF (infliximab) Response in Inflammatory Bowel Disease Patients
Author(s) -
MingHsi Wang,
Lawrence J. Timmons,
Andree Koop,
William J. Tremaine
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - Slovenian
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000777364.76967.26
Subject(s) - medicine , infliximab , adalimumab , inflammatory bowel disease , thiopurine methyltransferase , pharmacogenetics , pharmacogenomics , ulcerative colitis , crohn's disease , single nucleotide polymorphism , immunology , disease , gastroenterology , oncology , genotype , pharmacology , biochemistry , chemistry , gene